COVID Clinical Trial
Official title:
Clinical Course of COVID-19 in Patients With Rheumatoid Arthritis Treated With or Without Hydroxychloroquine: a Case-control Study
evaluation of the clinical course of COVID-19 in a cohort of patients with rheumatoid arthritis treated with or without hydroxychloroquine.
Study settings & sample:
This is an observational, retrospective -case-control, single-center study. This study will
include patients who meet the inclusion criteria followed in the Department of Rheumatology
and Rehabilitation, Tanta University Hospital, Tanta, Egypt.
Data will be taken from the medical records of patients with rheumatoid arthritis in the
outpatient clinic of the Rheumatology and Rehabilitation Department, Tanta University
Hospital, Tanta, Egypt. All patients will sign the informed consent form authorizing the
collection of these data.
Group classification A) Patients with rheumatoid arthritis using hydroxychloroquine as a part
of their treatment regimen.
b) Patients with rheumatoid arthritis not using hydroxychloroquine as a part of their
treatment regimen.
Data will be collected and analyzed from patient medical records. It will include the
following:
1. Epidemiologic, demographic, and clinical data.
2. Severity of rheumatoid arthritis.
3. Rheumatoid arthritis activity state using the Clinical Disease Activity Index
4. Dose and duration of hydroxychloroquine
5. Need for hospitalization, length of hospital stay, and ICU admission including the need
for mechanical ventilation.
6. Duration from the start of symptoms until clinical cure.
7. Severity of COVID-19 disease according to the World Health Organization interim guidance
8. Prognosis.
Laboratory investigations and imaging:
1. Complete blood count.
2. Renal and liver function tests.
3. Random blood sugar.
4. Lactate dehydrogenase, D-dimer.
5. Serum ferritin, C-reactive protein,
6. Chest radiographs or CT scan
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
| Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04420676 -
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
|
N/A | |
| Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
| Completed |
NCT04425317 -
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
|
N/A | |
| Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
| Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
| Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
| Completed |
NCT04425720 -
Use of Remote Monitoring for COVID-19 Patient
|
N/A | |
| Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
| Completed |
NCT04419610 -
RAS and Coagulopathy in COVID19
|
Early Phase 1 | |
| Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
| Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
| Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
| Not yet recruiting |
NCT04524156 -
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
|
N/A | |
| Completed |
NCT04441710 -
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
|
||
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Not yet recruiting |
NCT04392427 -
New Antiviral Drugs for Treatment of COVID-19
|
Phase 3 | |
| Terminated |
NCT04614025 -
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
|
Phase 2 | |
| Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 |